162 related articles for article (PubMed ID: 21689725)
1. Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.
Wasag B; Niedoszytko M; Piskorz A; Lange M; Renke J; Jassem E; Biernat W; Debiec-Rychter M; Limon J
Exp Hematol; 2011 Aug; 39(8):859-65.e2. PubMed ID: 21689725
[TBL] [Abstract][Full Text] [Related]
2. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
3. C-kit Asp-816-Val mutation analysis in patients with mastocytosis.
Verzijl A; Heide R; Oranje AP; van Schaik RH
Dermatology; 2007; 214(1):15-20. PubMed ID: 17191042
[TBL] [Abstract][Full Text] [Related]
4. Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT.
Foster R; Byrnes E; Meldrum C; Griffith R; Ross G; Upjohn E; Braue A; Scott R; Varigos G; Ferrao P; Ashman LK
Br J Dermatol; 2008 Nov; 159(5):1160-9. PubMed ID: 18795925
[TBL] [Abstract][Full Text] [Related]
5. Neonatal mastocytosis with pachydermic bullous skin without c-Kit 816 mutation.
Walker T; von Komorowski G; Scheurlen W; Dorn-Beineke A; Back W; Bayerl C
Dermatology; 2006; 212(1):70-2. PubMed ID: 16319478
[TBL] [Abstract][Full Text] [Related]
6. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
Noma K; Naomoto Y; Gunduz M; Matsuoka J; Yamatsuji T; Shirakawa Y; Nobuhisa T; Okawa T; Takaoka M; Tomono Y; Hiroyuki O; Gunduz E; Tanaka N
Oncol Rep; 2005 Sep; 14(3):645-50. PubMed ID: 16077968
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
[TBL] [Abstract][Full Text] [Related]
8. [Cutaneous mastocytosis].
Flageul B
Rev Prat; 2006 Oct; 56(16):1745-51. PubMed ID: 17315498
[TBL] [Abstract][Full Text] [Related]
9. c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation.
Yanagihori H; Oyama N; Nakamura K; Kaneko F
J Mol Diagn; 2005 May; 7(2):252-7. PubMed ID: 15858149
[TBL] [Abstract][Full Text] [Related]
10. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Guida T; Anaganti S; Provitera L; Gedrich R; Sullivan E; Wilhelm SM; Santoro M; Carlomagno F
Clin Cancer Res; 2007 Jun; 13(11):3363-9. PubMed ID: 17545544
[TBL] [Abstract][Full Text] [Related]
12. Activity of triptolide against human mast cells harboring the kinase domain mutant KIT.
Jin Y; Chen Q; Shi X; Lu Z; Cheng C; Lai Y; Zheng Q; Pan J
Cancer Sci; 2009 Jul; 100(7):1335-43. PubMed ID: 19383029
[TBL] [Abstract][Full Text] [Related]
13. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.
Longley BJ; Tyrrell L; Lu SZ; Ma YS; Langley K; Ding TG; Duffy T; Jacobs P; Tang LH; Modlin I
Nat Genet; 1996 Mar; 12(3):312-4. PubMed ID: 8589724
[TBL] [Abstract][Full Text] [Related]
14. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
[TBL] [Abstract][Full Text] [Related]
15. Familial urticaria pigmentosa: report of a family and review of the role of KIT mutations.
Fett NM; Teng J; Longley BJ
Am J Dermatopathol; 2013 Feb; 35(1):113-6. PubMed ID: 22892471
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
17. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
19. Kit signaling and negative regulation of daunorubicin-induced apoptosis: role of phospholipase Cgamma.
Plo I; Lautier D; Casteran N; Dubreuil P; Arock M; Laurent G
Oncogene; 2001 Oct; 20(46):6752-63. PubMed ID: 11709710
[TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
